XML 29 R5.htm IDEA: XBRL DOCUMENT v3.25.1
STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Total
Initial Public Offering
Convertible Promissory Notes
Initial Public Offering and Over-Allotment Option
2023 Private Placement
May 2024 Private Placement
October 2024 Private Placement
Convertible Preferred Stock Series A
Convertible Preferred Stock Series A
Initial Public Offering
Common Stock
Common Stock
Initial Public Offering
Common Stock
Initial Public Offering
Convertible Promissory Notes
Common Stock
Initial Public Offering and Over-Allotment Option
Common Stock
2023 Private Placement
Common Stock
May 2024 Private Placement
Common Stock
October 2024 Private Placement
Additional Paid-in Capital
Additional Paid-in Capital
Initial Public Offering
Additional Paid-in Capital
Initial Public Offering
Convertible Promissory Notes
Additional Paid-in Capital
Initial Public Offering and Over-Allotment Option
Additional Paid-in Capital
2023 Private Placement
Additional Paid-in Capital
May 2024 Private Placement
Additional Paid-in Capital
October 2024 Private Placement
Subscription Receivable
Accumulated Deficit
Balance at Dec. 31, 2022 $ (8,393,545)           $ 8,793,637   $ 259             $ 681,106               $ (17,868,547)
Beginning balance, shares at Dec. 31, 2022             7,500,713   2,590,197                              
Conversion of convertible instruments upon offering   $ 12,965,480           $ (8,793,637)   $ 132 $ 274           $ 8,793,505 $ 12,965,206            
Conversion of convertible instruments upon offering (in shares)               (7,500,713)   1,316,926 2,736,488                          
Sale of common stock , net of issuance costs     $ 14,136,428 $ 23,952,887               $ 329 $ 437           $ 14,136,099 $ 23,952,450        
Sale of common stock, net of issuance costs (in shares)                       3,287,804 4,370,382                      
Exercise of stock options 89,947               $ 8             89,939                
Exercise of stock options (in shares)                 85,528                              
Exercise of warrants                               11,250             $ (11,250)  
Exercise of warrants (in shares)                 1,500                              
Stock-based compensation expense and vesting of restricted stock units 872,248               $ 2             872,246                
Stock-based compensation expense and vesting of restricted stock units (in shares)                 16,500                              
Net loss (7,987,836)                                             (7,987,836)
Balance at Dec. 31, 2023 35,635,609           $ 0   $ 1,441             61,501,801             (11,250) (25,856,383)
Ending balance, shares at Dec. 31, 2023             0   14,405,325                              
Sale of common stock , net of issuance costs         $ 4,943,668 $ 9,060,713               $ 60 $ 138           $ 4,943,608 $ 9,060,575    
Sale of common stock, net of issuance costs (in shares)                           603,136 1,379,314                  
Exercise of stock options $ 1,975                             1,975                
Exercise of stock options (in shares) 1,829               1,829                              
Proceeds from subscription receivable $ 11,250                                           11,250  
Exercise of warrants 2,141,128               $ 31             2,141,097                
Exercise of warrants (in shares)                 312,837                              
Stock-based compensation expense and vesting of restricted stock units 2,663,539               $ 1             2,663,538                
Stock-based compensation expense and vesting of restricted stock units (in shares)                 5,000                              
Net loss (14,880,787)                                             (14,880,787)
Balance at Dec. 31, 2024 $ 39,577,095           $ 0   $ 1,671             $ 80,312,594             $ 0 $ (40,737,170)
Ending balance, shares at Dec. 31, 2024             0   16,707,441